Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies

Table 4 Pooled incidences of selected toxicities

Adverse events	Studies(t)	Act-D-based regimen (n = 687)		MTX-based regimen (n = 987)
Adverse events	Studies(t)	Patients(n₁/n₂)	%	Patients(n₁/n₂)	%
Hematologic disorders
Anemia	2	46/129	35.7	37/127	29.1
Leucocytopenia	3	27/208	13.0	24/182	13.2
Neutropenia	5	31/259	12.0	26/264	9.8
Thrombocytopnia	5	18/248	7.3	9/221	4.1
Gastrointestinal disorders
Constipation	3	32/134	23.9	19/110	17.3
Diarrhea	5	29/308	9.4	35/348	10.1
Nausea	9	167/405	41.2	85/427	19.9
Vomiting	9	92/436	21.1	43/449	9.6
Others
Alopecia	7	69/232	29.7	19/207	9.2
Anorexia	3	13/130	10.0	9/138	6.5
Fatigue	3	84/134	62.7	60/110	54.5
Liver toxicity	5	11/223	4.9	28/223	12.6

Act-D Actinomycin D, MTX Methotrexate, t The number of studies reporting the toxicity, n Total number of enrolled patients, n1 The number of patients with adverse events, n2 the total number of patients from studies reporting the toxicity

ISSN: 1471-2407